Interview with Eugenio Aringhieri, CEO, Dompe
You recently declared that in a context of new emerging challenges for pharmaceutical companies, those who would survive would not be the strongest ones but the most responsive to change.…
Assogenerici (National Association of Generic Drugs Industries) is the official representative body of the industry of generic drugs and biosimilars in Italy, at the forefront in providing medicines at affordable prices and high quality for millions of citizens, helping to boost competition and innovation in the pharmaceutical sector. Associated companies both small and medium corporations for a wide range of drugs, by perfusion with Galen to traditional generics to cutting biosimilars, is distributed in pharmacies at public hospitals.
Established in 1993, Assogenerici represents over 50 pharmaceutical companies. The companies represented in Assogenerici provide 10,000 direct jobs in Italy over the important induced, highly specialized. Generic drugs generate over € 400 million of savings per year for the NHS and for patients, helping to ensure patient access to essential drugs releasing at the same time, valuable resources for new and expensive drug therapies.
Assogenerici plays an important advisory role in the Italian health sector. Assogenerici and its members are working with the Italian and European institutions to develop sustainable solutions for pharmaceutical care and to increase the competitive strength of Italy in the world pharmaceutical market.
Passeggiata di Ripetta, 22 – int. 1 – 00186 – Roma
Tel: +39.06.59.60.53.24
Fax: +39.06.54.31.323
E-mail: info@assogenerici.it
Posta Elettronica Certificata: assogenerici@pec.
Web: assogenerici.it
You recently declared that in a context of new emerging challenges for pharmaceutical companies, those who would survive would not be the strongest ones but the most responsive to change.…
Takeda has more than 25 years of history in Italy and reached the 20th position in the Italian market- a striking performance in a context when it is still rare…
The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could…
Ten years of experience in the Dendrite group enabled you to cover a number of international positions, before its acquisition by Cegedim in May 2007. How has the integration progressed…
Novo Nordisk is one of the very few pharmaceutical multinationals that has such a strong focus on one therapeutic area. Although the company is now diversifying, diabetes remains its leading…
Mr. Medda, Teva’s Italian history is relatively young, could you describe the main facts that describe Teva presence in Italy? Teva Italia was founded in 1996 and is currently the…
Italfarmaco counts amongst the few players who really sustained the growth of the Italian pharmaceutical industry in the past 10 years. Which specific values would you quote as keys to…
You created Abiogen in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition, keeping building on the legacy of your great-grandfather Commendatore…
Finderm is the result of a courageous entrepreneurial experience, since you initiated the operations in 1995, in the most challenging times for the Italian pharmaceutical industry. Could you briefly introduce…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
You declared in a recent interview that Zambon Group will always keep complying with the vision of your father Alberto, who has always refused acquisition offers from multinationals- a striking…
You are specialised in Cardiology at Padua University, in Tropical Medicine and Hygiene at London University and in Pharmacology at Modena University, in Communication at Bocconi University in Milan, and…
See our Cookie Privacy Policy Here
